| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Bezisterim | HE-3286; NE-3107 | Phase 3 Clinical | Harbor Therapeutics, Biovie Inc | Diabetes Mellitus, Type 2; Brain Injuries, Traumatic; Insulin Resistance; Arthritis, Rheumatoid; Post-Acute COVID-19 Syndrome; Alzheimer Disease; Colitis, Ulcerative; Parkinson Disease | Details |
| PN-235 | JNJ-77242113; PN-235; JNJ-2113; PN-21235; JNJ-77242113-AAC | Phase 3 Clinical | Protagonist Therapeutics Inc | Psoriasis; Colitis, Ulcerative; Plaque psoriasis | Details |
| PN-232 | PN-232; JNJ75105186 | Phase 1 Clinical | Protagonist Therapeutics Inc | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ustekinumab biosimilar (Samsung Bioepis) | SB-17; SB17 | Approved | Samsung Bioepis Co Ltd | Pyzchiva | EU | Crohn Disease; Colitis, Ulcerative | Samsung Bioepis Nl Bv | 2024-04-19 | Gastrointestinal Diseases; Skin Diseases; Psoriasis; Arthritis, Psoriatic; Rheumatic Diseases; Colitis, Ulcerative; Inflammation; Crohn Disease; Plaque psoriasis | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



